Earnings ·
Scribe Therapeutics reported a net loss of $6.5 million ($2.62 per share) for the quarter ended June 30, 2026…
SCTXScribe Therapeutics, Inc.
Scribe Therapeutics reported a net loss of $6.5 million ($2.62 per share) for the quarter ended June 30, 2026, compared to a $9.9 million loss in the prior year period. The company raised approximately $155.5 million in aggregate gross proceeds from its initial public offering and concurrent private placement with Sanofi, bringing total cash resources to roughly $183.6 million, which funds operations into the first half of 2029. Pipeline updates include initiating a Phase 1 trial for STX-1150, an epigenetic silencing therapy targeting LDL-C, and receiving over $25 million in CIRM grants to advance STX-1200 and STX-1400 toward clinical entry. Scribe Therapeutics is a clinical-stage biotechnology company engineering CRISPR-based technologies for cardiometabolic diseases.